<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Journal of Blood and Cancer</title>
<title_fa></title_fa>
<short_title>Iranian Journal of Blood and Cancer</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijbc.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2008-4595</journal_id_issn>
<journal_id_issn_online>2008-4609</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.61882/ijbc</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>2008-4595</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2022</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>14</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Rare Absence of CD79alpha in B-ALLs is not Associated with Altered Prognosis</title>
	<subject_fa>Adults Hematology &amp; Oncology</subject_fa>
	<subject>Adults Hematology &amp; Oncology</subject>
	<content_type_fa>متا آنالیز</content_type_fa>
	<content_type>Meta-analysis</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;line-height:2;&quot;&gt;&lt;span style=&quot;font-family:Arial;&quot;&gt;&lt;span style=&quot;font-size:14px;&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; The diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) on the basis of the World Health Organization (WHO) recommendations in 2016 requires the expression of CD19 with CD79a (CD79a), cCD22 and CD10. CD79a is an integral B cell antigen expressed at all stages. Its absence in B-ALL has only been rarely reported. In this study, we described three cases of B-ALL showing complete loss or extremely weak expression of CD79a.&lt;br&gt;
&lt;strong&gt;Methods:&lt;/strong&gt; Seventy-five patients with B-ALL diagnosed by flow cytometry over a period of 3.5 years were taken out from the records. Cases lacking for CD79a by flow cytometry were further analysed.&lt;br&gt;
&lt;strong&gt;Results: &lt;/strong&gt;Out of 75 cases, CD 79a negativity was seen in 4% (3/75). However, every three cases expressed other B cell markers. No aberrant expression of myeloid and lymphoid antigens was seen in any of these three cases. The prognosis of these three cases was similar to CD79a positive cases.&lt;br&gt;
&lt;strong&gt;Conclusion: &lt;/strong&gt;Rarely, B cell ALL may lack CD79a. Thus, to avoid the misdiagnosis, a comprehensive antibody panel should be used. There was no prognostic impact of CD79a negativity in this study, however larger studies are needed to confirm these results.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>B-cell acute lymphoblastic leukemia, CD79a expression, Flow cytometry, Immunophenotyping, Prognosis</keyword>
	<start_page>29</start_page>
	<end_page>32</end_page>
	<web_url>http://ijbc.ir/browse.php?a_code=A-10-586-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Neha</first_name>
	<middle_name></middle_name>
	<last_name>Garg</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846009004</code>
	<orcid>10031947532846009004</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>senior Resident, Department of Pathology, UCMS and GTBH</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Malvika</first_name>
	<middle_name></middle_name>
	<last_name>Shastri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846009005</code>
	<orcid>10031947532846009005</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Junior Resident,Department of Pathology, UCMS and GTBH</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mrinalini</first_name>
	<middle_name></middle_name>
	<last_name>kotru</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>10031947532846009006</code>
	<orcid>10031947532846009006</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Professor, Department of Pathology, UCMS and GTBH</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Richa</first_name>
	<middle_name></middle_name>
	<last_name>Gupta</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>richagupta0209@gmail.com</email>
	<code>10031947532846009007</code>
	<orcid>10031947532846009007</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Professor, Department of Pathology, UCMS and GTBH</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
